Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

TEIKYO UNIVERSITY

Home Clinical Trial Sponsors and OrganizationsTEIKYO UNIVERSITY

TEIKYO UNIVERSITY

ACTIVE

2-11-1, KAGA, Itabashi-Ku, Tokyo, Japanwww.teikyo-u.ac.jpPrivateEstablished: 1996-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

76

6 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

1996

Overview

Trial Phase Distribution

Phase

Trials

Share

Not Applicable

57

75.0%

Unknown

4

5.3%

Phase 1

3

4.0%

Phase 4

2

2.6%

Phase 3

1

1.3%

Trial Status Distribution

Completed

36

47.4%

Not yet recruiting

6

7.9%

Recruiting

30

39.5%

Unknown

3

4.0%

Clinical Trials

Trials sponsored by this organization (76)

A Phase 1, placebo-controlled, randomized, participant- and assessor-blind, single-center study to assess the safety and immunogenicity of 2 dose levels of Nipah measles vector (MV-NiV) vaccine administered subcutaneously either as a single dose or as 2 consecutive doses at 4-week interval, in healthy non-exposed volunteers, aged 18-40 years

Mar 202660 participants

Ramucirumab plus Erlotinib as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR exon 21 L858R mutation: A multicenter retrospective observational cohort study in Japan (REAL-SPEED)

Not yet recruiting

Sep 2023200 participants

Diagnosis of patent foramen ovale in saline contrast transthoracic echocardiography using the party balloon inflation maneuver: A multi-center registry

Aug 2023100 participants

PolyMyXin-B direct hemoperfusion OPTimal Initiation timing with Catecholamine study (PMX-OPTIC study)

Jun 2023600 participants

Predictive accuracy of the MASCC and CISNE scores for selecting febrile neutropenia patients as candidates for outpatient treatment: A systematic review and meta-analysis.

Not yet recruiting

Impact of hemostatic function assessed by Total Thrombus-formation Analysis System (T-TAS01) on bleeding events during transcatheter aortic valve replacement

Aug 2022200 participants

Multicenter Retrospective Study to Evaluate Necitumumab plus Cisplatin/Gemcitabine after Immune-check-point inhibitors in Advanced Squamous-Cell Lung Cancer in Japan (NINJA study)

Aug 202260 participants

Prediction of periprocedural Bleeding Event during enDoScopIc submucosal DissEction using total thrombus-formation analysis system study

Not yet recruiting

Aug 2022150 participants

Page 1 of 10

Approvals

No approval data available

News

AI-Designed Protein and Needle-Based Endoscope Overcome Dual Barriers to Photothermal Cancer Therapy

- Researchers used AlphaFold to design IDP1, a biodegradable protein coating that extended nanoparticle circulation time more than fourfold compared to PEG in mouse models. - An ultra-thin rigid endoscope fitting inside a 16-gauge needle delivers laser light directly into tumors, using 28% less power while maintaining efficacy. - In colon cancer-bearing mice, a single dose of IDP1-coated nanoparticles plus one laser treatment eliminated tumors within 14 days with no recurrence over 40 days. - The team plans safety studies and will test the platform in head and neck, esophageal, and pancreatic cancers reachable by endoscope.

On this page

Overview
Clinical Trials76
Approvals
News1

Back to Organizations